Leerink Partnrs Comments on United Therapeutics Co.’s Q1 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Leerink Partnrs increased their Q1 2024 EPS estimates for shares of United Therapeutics in a report issued on Tuesday, March 26th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $5.90 per share for the quarter, up from their previous forecast of $5.87. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.32 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.26 EPS and FY2024 earnings at $25.95 EPS.

Several other equities analysts have also recently issued reports on UTHR. Wedbush reiterated an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their target price for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Finally, SVB Leerink began coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.40.

United Therapeutics Stock Down 1.9 %

UTHR stock opened at $243.27 on Thursday. The firm’s fifty day simple moving average is $225.55 and its 200-day simple moving average is $227.39. The company has a market capitalization of $11.45 billion, a P/E ratio of 12.26 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.67 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in UTHR. Atlas Capital Advisors LLC purchased a new position in United Therapeutics in the fourth quarter worth approximately $51,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 49.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after buying an additional 65 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Neo Ivy Capital Management purchased a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $48,000. Finally, Zions Bancorporation N.A. purchased a new stake in shares of United Therapeutics during the 1st quarter worth approximately $66,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $227.97, for a total transaction of $1,367,820.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $8,343,474.03. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $227.97, for a total transaction of $1,367,820.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $8,343,474.03. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $32,282.90. The disclosure for this sale can be found here. Insiders sold 76,680 shares of company stock worth $17,886,630 over the last three months. Insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.